TITLE

Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models

AUTHOR(S)
Tao, Leilei; Huang, Guichun; Shi, Shujing; Chen, Longbang
PUB. DATE
January 2014
SOURCE
Medical Oncology;Jan2014, Vol. 31 Issue 1, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
93504267

 

Related Articles

  • Beyond chemotherapy and targeted therapy: adoptive cellular therapy in non-small cell lung cancer. Wang, Junying; Wang, Xueju // Molecular Biology Reports;Sep2014, Vol. 41 Issue 9, p6317 

    Non-small cell lung cancer (NSCLC) is an intractable disease for which effective treatment approaches are urgently needed. The ability to induce antigen-specific immune responses in patients with lung cancer has led to the development of immunotherapy as a novel concept for the treatment of...

  • Combining Antiangiogenic Therapy with Adoptive Cell Immunotherapy Exerts Better Antitumor Effects in Non-Small Cell Lung Cancer Models. Shi, Shujing; Wang, Rui; Chen, Yitian; Song, Haizhu; Chen, Longbang; Huang, Guichun // PLoS ONE;Jun2013, Vol. 8 Issue 6, p1 

    Introduction: Cytokine-induced killer cells (CIK cells) are a heterogeneous subset of ex-vivo expanded T lymphocytes which are characterized with a MHC-unrestricted tumor-killing activity and a mixed T-NK phenotype. Adoptive CIK cells transfer, one of the adoptive immunotherapy represents a...

  • IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. Helms, Mike W.; Prescher, Jennifer A.; Yu-An Cao; Schaffert, Steven; Contag, Christopher H. // Cancer Immunology, Immunotherapy;Sep2010, Vol. 59 Issue 9, p1325 

    Cytokine-induced killer (CIK) cells are T cell derived ex vivo expanded cells with both NK and T cell properties. They exhibit potent anti-tumor efficacy against various malignancies in preclinical models and have proven safe and effective in clinical studies. We combined CIK cell adoptive...

  • Effects of MICA Expression on the Prognosis of Advanced Non-Small Cell Lung Cancer and the Efficacy of CIK Therapy. Chen, Yu; Lin, Gen; Guo, Zeng-qing; Zhou, Zhi-feng; He, Zhi-yong; Ye, Yun-bin // PLoS ONE;Jul2013, Vol. 8 Issue 7, p1 

    Objective: To investigate the clinical significance of the expression of MHC class I chain-related gene A (MICA) in patients with advanced non-small cell lung cancer and explore the relationship between MICA expression and the efficacy of cytokine-induced killer cell (CIK) therapy for treating...

  • The phenotype of ex vivo generated cytokine-induced killer cells is associated with overall survival in patients with cancer. Pan, Ke; Wang, Qi-Jing; Liu, Qing; Zheng, Hai-Xia; Li, Yong-Qiang; Weng, De-Sheng; Li, Jian-Jun; Huang, Li-Xi; He, Jia; Chen, Shi-Ping; Ke, Miao-La; Zeng, Yi-Xin; Xia, Jian-Chuan // Tumor Biology;Jan2014, Vol. 35 Issue 1, p701 

    Cytokine-induced killer (CIK) cells are ex vivo generated heterogeneous NK-like T lymphocytes. It is not very clear whether the phenotype of CIK cells is associated with their therapeutic efficacy to cancer patients. Thus, in this study, the association of phenotype of CIK cells and the overall...

  • Cytokine-induced killer cells promote antitumor immunity. Jingting Jiang; Changping Wu; Binfeng Lu // Journal of Translational Medicine;2013, Vol. 11 Issue 1, Special section p1 

    The number of immune cells, especially dendritic cells and cytotoxic tumor infiltrating lymphocytes (TIL), particularly Th1 cells, CD8 T cells, and NK cells is associated with increased survival of cancer patients. Such antitumor cellular immune responses can be greatly enhanced by adoptive...

  • Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer. Pan, Qiu-Zhong; Tang, Yan; Wang, Qi-Jing; Li, Yong-Qiang; Zhang, Li; Li, Xiao-Dong; Zhao, Jing-Jing; Weng, De-Sheng; Liu, Qing; Huang, Li-Xi; He, Jia; Chen, Shi-Ping; Ke, Miao-La; Zeng, Yi-Xin; Xia, Jian-Chuan // OncoImmunology;Sep2015, Vol. 4 Issue 9, pN.PAG 

    Postoperative non-small cell lung cancer (NSCLC) patients require adjuvant therapy to improve their prognosis. In this study, we investigated the efficacy of a sequential combination of autologous cellular immunotherapy (CIT) and chemotherapy for postoperative NSCLC. This retrospective study...

  • IN BRIEF.  // Hem/Onc Today;6/25/2010, Vol. 11 Issue 12, p35 

    This section presents information on two drug efficacy studies including one on bevacizumab for men with metastatic castration-resistant prostate cancer, and another on erlotinib for patients with nonsmall cell lung cancer.

  • The CIK cells stimulated with combination of IL-2 and IL-15 provide an improved cytotoxic capacity against human lung adenocarcinoma. Wei, Chuanyu; Wang, Wenju; Pang, Wei; Meng, Mingyao; Jiang, Lihong; Xue, Sha; Xie, Yanhua; Li, Ruhong; Hou, Zongliu // Tumor Biology;Mar2014, Vol. 35 Issue 3, p1997 

    Generation of cytokine-induced killer (CIK) cells is an emerging approach in adoptive donor lymphocyte infusion for patients with a wide range of tumors. However, our previous in vitro studies have shown that the killing efficacy of CIK cells against lung cancer was lower than other tumor cells,...

  • Maintenance bevacizumab plus pemetrexed improved PFS in advanced NSCLC.  // Hem/Onc Today;9/10/2013, Vol. 14 Issue 17, p22 

    The article discusses a study published in a 2013 issue of the "Journal of Clinical Oncology" that examined the efficacy of continued maintenance with bevacizumab plus pemetrexed in improving progression-free survival (PFS) in patients with nonsquamous non-small cell lung cancer (NSCLC).

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics